blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3319994

EP3319994 - MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.12.2024
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  05.01.2024
FormerGrant of patent is intended
Status updated on  31.08.2023
FormerExamination is in progress
Status updated on  11.02.2019
FormerRequest for examination was made
Status updated on  13.04.2018
FormerThe international publication has been made
Status updated on  13.01.2017
Most recent event   Tooltip13.03.2026Lapse of the patent in a contracting state
New state(s): HU		published on 15.04.2026 [2026/16]
Applicant(s)For all designated states
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, NY 10591 / US
[2018/20]
Inventor(s)01 / ANDREEV, Julian
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
02 / THAMBI, Nithya
2406 Rosemont Terrace
Furlong, PA 18925 / US
03 / DELFINO, Frank
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
04 / MARTIN, Joel
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
05 / THURSTON, Gavin
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
06 / CYGNAR, Katherine
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
07 / PAPADOPOULOS, Nicholas
c/o Regeneron Pharmaceuticals Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591 / US
 [2018/20]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2024/06]
Former [2018/20]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date16741208.906.07.2016
[2018/20]
WO2016US41055
Priority number, dateUS201562188860P06.07.2015         Original published format: US 201562188860 P
US201662328900P28.04.2016         Original published format: US 201662328900 P
US201662347179P08.06.2016         Original published format: US 201662347179 P
[2018/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017007796
Date:12.01.2017
Language:EN
[2017/02]
Type: A1 Application with search report 
No.:EP3319994
Date:16.05.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 12.01.2017 takes the place of the publication of the European patent application.
[2018/20]
Type: B1 Patent specification 
No.:EP3319994
Date:07.02.2024
Language:EN
[2024/06]
Search report(s)International search report - published on:EP12.01.2017
ClassificationIPC:C07K16/32, C07K16/28, C07K16/46, C07K16/22, C07K16/18, C07K16/12, C07K14/435, A61K39/395, A61K47/68, A61P35/00
[2023/30]
CPC:
C07K16/1203 (EP,IL,US); A61K47/6803 (IL); A61K39/39558 (KR);
A61K47/68033 (EP,US); A61K47/6819 (KR); A61K47/6849 (EP,IL,US);
A61K47/6851 (EP,IL,US); A61K47/6855 (EP,IL,KR,US); A61K47/6879 (EP,IL,KR,US);
A61P35/00 (EP,IL,KR,US); C07K14/4702 (EP,IL,US); C07K16/18 (EP,IL,US);
C07K16/22 (EP,IL,US); C07K16/28 (EP,IL,US); C07K16/2833 (EP,IL,US);
C07K16/2866 (EP,IL,US); C07K16/2869 (EP,IL,US); C07K16/2896 (EP,IL,US);
C07K16/30 (IL,US); C07K16/32 (EP,IL,US); C07K16/468 (IL,US);
C12N9/6454 (EP,IL,US); A61K2039/505 (KR); A61K2039/507 (IL,US);
A61K2039/572 (IL,US); C07K2317/21 (IL,US); C07K2317/31 (EP,IL,US);
C07K2317/35 (IL,US); C07K2317/76 (IL,US); C07K2317/77 (EP,IL,US);
C07K2319/00 (EP,IL,US); C07K2319/30 (EP,IL,US) (-)
Former IPC [2018/20]C07K16/28, C07K16/46, C07K16/22, C07K16/12, C07K16/32, C07K16/18, C07K14/435
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/20]  
Extension statesBA02.02.2018
ME02.02.2018
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:MULTISPEZIFISCHE ANTIGENBINDUNGSMOLEKÜLE UND VERWENDUNGEN DAVON[2018/20]
English:MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF[2018/20]
French:MOLÉCULES MULTISPÉCIFIQUES DE LIAISON À L'ANTIGÈNE ET LEURS UTILISATIONS[2018/20]
Entry into regional phase02.02.2018National basic fee paid 
02.02.2018Designation fee(s) paid 
02.02.2018Examination fee paid 
Examination procedure02.02.2018Examination requested  [2018/20]
02.02.2018Date on which the examining division has become responsible
10.09.2018Amendment by applicant (claims and/or description)
14.02.2019Despatch of a communication from the examining division (Time limit: M06)
21.08.2019Reply to a communication from the examining division
09.01.2020Despatch of a communication from the examining division (Time limit: M04)
07.05.2020Reply to a communication from the examining division
06.08.2020Despatch of a communication from the examining division (Time limit: M02)
13.10.2020Reply to a communication from the examining division
01.09.2023Communication of intention to grant the patent
21.12.2023Fee for grant paid
21.12.2023Fee for publishing/printing paid
21.12.2023Receipt of the translation of the claim(s)
Divisional application(s)EP20173448.0  / EP3722318
Opposition(s)08.11.2024No opposition filed within time limit [2025/03]
Fees paidRenewal fee
24.07.2018Renewal fee patent year 03
22.07.2019Renewal fee patent year 04
22.07.2020Renewal fee patent year 05
20.07.2021Renewal fee patent year 06
21.07.2022Renewal fee patent year 07
20.07.2023Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY06.07.2016
HU06.07.2016
CZ07.02.2024
HR07.02.2024
MC07.02.2024
PL07.02.2024
RO07.02.2024
SK07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
[2026/16]
Former [2025/51]CY06.07.2016
CZ07.02.2024
HR07.02.2024
MC07.02.2024
PL07.02.2024
RO07.02.2024
SK07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2025/11]CZ07.02.2024
HR07.02.2024
MC07.02.2024
PL07.02.2024
RO07.02.2024
SK07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/49]CZ07.02.2024
HR07.02.2024
PL07.02.2024
RO07.02.2024
SK07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/48]CZ07.02.2024
HR07.02.2024
PL07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/47]HR07.02.2024
PL07.02.2024
SM07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/36]HR07.02.2024
PL07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/34]HR07.02.2024
NO07.05.2024
RS07.05.2024
GR08.05.2024
IS07.06.2024
Former [2024/33]NO07.05.2024
IS07.06.2024
Former [2024/32]IS07.06.2024
Cited inInternational search[I] WO2013138400  (REGENERON PHARMA et al.) [I] 1-3 * the whole document *
 [A]   JOHN M. LAMBERT ET AL: "Ado-trastuzumab Emtansine (T-DM1): An Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, no. 16, 28 August 2014 (2014-08-28), US, pages 6949 - 6964, XP055264705, ISSN: 0022-2623, DOI: 10.1021/jm500766w [A] 1-3 * whole document, especially the Abstract *

DOI:   http://dx.doi.org/10.1021/jm500766w
ExaminationWO2014182970
 WO2015026907
   G. D. L. PHILLIPS ET AL: "Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy", CLINICAL CANCER RESEARCH, vol. 20, no. 2, 4 October 2013 (2013-10-04), pages 456 - 468, XP055197050, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-13-0358

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-13-0358
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.